Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Esophageal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Participants undergo upper GI endoscopy with endoscopic mucosal resection (EMR) and/or radiofrequency ablation (RFA) of esophageal squamous dysplasia (ESD). After initial therapy participants undergo repeat endoscopy every 3 months for a year, with re-biopsy and re-treatment of residual ESD as appropriate.

Endoscopic Mucosal Resection (EMR)

Endoscopic radiofrequency ablation of regions of ESD

Radiofrequency ablation

Stephen L Burgert, MD

Esophageal cancer is common in Kenya. The precursor of esophageal cancer is esophageal squamous dysplasia (ESD). In this study, persons known to have ESD will undergo endoscopic removal or ablation of ESD in order to prevent development of esophageal cancer.

Esophageal squamous dysplasia (ESD) is the precursor lesion of esophageal squamous cell cancer. ESD causes no symptoms but can be detected by screening. ESD may harbor various grades of dysplasia. Patients with moderate grade or high grade dysplasia (MGD or HGD) have up to a 40-fold increased risk of esophageal squamous cell cancer.

In this study, persons known to have ESD with MGD or HGD on the basis of prior screening will be invited to undergo endoscopic treatment with either endoscopic mucosal resection (EMR) and/or radio frequency ablation (RFA) in order to remove or ablate regions of ESD. Participants will undergo a series of endoscopies to treat ESD and monitor success of treatment.

Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital

Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital (The EXPECT Trial) by Removal or Ablation of Esophageal Squamous Cell Dysplasia

The percentage of subjects demonstrating complete response defined as complete histological clearance of MGD, HGD and esophageal squamous carcinoma in the treatment areas at 12 months after the initial ablation procedure.

Percentage of participants experiencing serious adverse events following EMR or RFA treatment.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital	NCT02146508	Esophageal Canc... Esophageal Squa...	Endoscopic Muco... Radiofrequency ...	18 Years - 85 Years	Tenwek Hospital
Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital	NCT02146508	Esophageal Canc... Esophageal Squa...	Endoscopic Muco... Radiofrequency ...	18 Years - 85 Years	Tenwek Hospital

Spots Global Cancer Trial Database for radiofrequency, catheter ablation